BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the ...

BridgeBio Pharma Inc. (BBIO) announced that the U.S. Food and Drug Administration approved Attruby or acoramidis, an ...

The oral drug, branded as Attruby, was approved to treat adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM), ...

New drugs and therapies have become indispensable for treating an array of cancers. Unfortunately, they can also cause damage to the heart, a side effect that has led to the development of a new ...

Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

One Newly Reported Cardiac Biopsy Result from Cohort 2 ... well tolerated to date across all dose cohorts with no reports of amyloid-related imaging abnormalities (ARIA). A dose and time-dependent ...

Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s ...

Immunohistochemistry, immune-electron microscopy, and proteomic analyses can be used for amyloid typing. Endomyocardial biopsy is the gold standard for the diagnosis and characterization of cardiac ...

Cardiac arrest (when the heart stops beating) interrupts circulation, causing brain cells to start dying in less than five minutes of the brain going without needed oxygen in the blood. The ...